Takeda enlists Singapore's talent to drive forward vaccine development

9 March 2018

Takeda’s (TYO: 4502) latest move to boost its fast-growing global vaccines business is to set up a Center of Excellence (CoE) in Singapore.

The Japanese drugmaker, which only set up its Global Vaccine Business Unit six years ago under the leadership of Rajeev Venkayya, has agreed a multi-year partnership with the Singapore Economic Development Board to support the recruitment and training of local talent in the development of new vaccine manufacturing technologies.

These recruits will work on Takeda’s current and future vaccines candidates, especially those to address diseases which present some of the world’s most challenging health problems, such as dengue, Zika and polio.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK